Epidemiology, Resource Use, and Treatment Patterns of Locally Advanced or Metastatic Urothelial Carcinoma in France

Overview

Journal Future Oncol

Specialty Oncology

Date 2025 Feb 20

PMID 39973175

Authors

Florence Joly

Stephane Culine

Morgan Roupret

Aurore Tricotel

Emilie Casarotto

Sandrine Brice

Rafael Minacori

Marthe Vuillet

Marie-Catherine Thomas

Kirsten Leyland

Anil Upadhyay

Vicki Munro

Torsten Strunz-McKendry

Affiliations

Soon will be listed here.

Abstract

Aim: Describe real-world epidemiology, treatment patterns, health care resource utilization, and costs of locally advanced or metastatic urothelial carcinoma (la/mUC) in France.

Patients & Methods: Retrospective study including all adults with la/mUC diagnosis during January 2017 to December 2020 in the PMSI database.

Results: Annual prevalence and incidence ranged from 36.4 to 38.9 and 16.4 to 18.5 cases per 100,000 people, respectively. Of the 25,314 patients with incident la/mUC, 37.6% did not receive first-line systemic treatment. Of the 14,656 patients who started first-line systemic treatment, 66.6%, 22.5%, and 10.9% received 1, 2, and 3 lines of therapy, respectively. Annual per-patient costs in second-/third-line setting ranged from €8803 to €16,012.

Conclusion: The substantial disease burden of la/mUC in France highlights the unmet need for new therapies.

References

Roupret M, Pignot G, Masson-Lecomte A, Comperat E, Audenet F, Roumiguie M . [French ccAFU guidelines - update 2020-2022: bladder cancer]. Prog Urol. 2020; 30(12S):S78-S135. DOI: 10.1016/S1166-7087(20)30751-X. View

Poulalhon C, Rotelli-Bihet L, Moine S, Fagot-Campagna A, Aubry R, Tuppin P . Use of hospital palliative care according to the place of death and disease one year before death in 2013: a French national observational study. BMC Palliat Care. 2018; 17(1):75. PMC: 5954461. DOI: 10.1186/s12904-018-0327-z. View

Neuzillet Y, Audenet F, Loriot Y, Allory Y, Masson-Lecomte A, Leon P . French AFU Cancer Committee Guidelines - Update 2022-2024: Muscle-Invasive Bladder Cancer (MIBC). Prog Urol. 2022; 32(15):1141-1163. DOI: 10.1016/j.purol.2022.07.145. View

Dreyer N . Advancing a Framework for Regulatory Use of Real-World Evidence: When Real Is Reliable. Ther Innov Regul Sci. 2018; 52(3):362-368. PMC: 5944086. DOI: 10.1177/2168479018763591. View

Bannay A, Chaignot C, Blotiere P, Basson M, Weill A, Ricordeau P . The Best Use of the Charlson Comorbidity Index With Electronic Health Care Database to Predict Mortality. Med Care. 2015; 54(2):188-94. DOI: 10.1097/MLR.0000000000000471. View

Powles T, Bellmunt J, Comperat E, De Santis M, Huddart R, Loriot Y . Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2021; 33(3):244-258. DOI: 10.1016/j.annonc.2021.11.012. View

Bergot E, de Leotoing L, Bendjenana H, Tournier C, Vainchtock A, Nachbaur G . Hospital burden of pulmonary arterial hypertension in France. PLoS One. 2019; 14(9):e0221211. PMC: 6752797. DOI: 10.1371/journal.pone.0221211. View

Boudemaghe T, Belhadj I . Data Resource Profile: The French National Uniform Hospital Discharge Data Set Database (PMSI). Int J Epidemiol. 2017; 46(2):392-392d. DOI: 10.1093/ije/dyw359. View

Milloy N, Kirker M, Unsworth M, Montgomery R, Kluth C, Kearney M . Real-World Analysis of Treatment Patterns and Platinum-Based Treatment Eligibility of Patients With Metastatic Urothelial Cancer in 5 European Countries. Clin Genitourin Cancer. 2023; 22(1):e136-e147.e1. DOI: 10.1016/j.clgc.2023.09.010. View

10.

Bloudek L, Wright P, McKay C, Derleth C, Lill J, Lenero E . Systematic Literature Review (SLR) and Network Meta-Analysis (NMA) of First-Line Therapies (1L) for Locally Advanced/Metastatic Urothelial Carcinoma (la/mUC). Curr Oncol. 2023; 30(4):3637-3647. PMC: 10136539. DOI: 10.3390/curroncol30040277. View

11.

Leal J, Luengo-Fernandez R, Sullivan R, Witjes J . Economic Burden of Bladder Cancer Across the European Union. Eur Urol. 2015; 69(3):438-47. DOI: 10.1016/j.eururo.2015.10.024. View

12.

Berdik C . Unlocking bladder cancer. Nature. 2017; 551(7679):S34-S35. DOI: 10.1038/551S34a. View

13.

Palmaro A, Moulis G, Despas F, Dupouy J, Lapeyre-Mestre M . Overview of drug data within French health insurance databases and implications for pharmacoepidemiological studies. Fundam Clin Pharmacol. 2016; 30(6):616-624. DOI: 10.1111/fcp.12214. View

14.

Carrigan G, Whipple S, Taylor M, Torres A, Gossai A, Arnieri B . An evaluation of the impact of missing deaths on overall survival analyses of advanced non-small cell lung cancer patients conducted in an electronic health records database. Pharmacoepidemiol Drug Saf. 2019; 28(5):572-581. PMC: 6594237. DOI: 10.1002/pds.4758. View

15.

Dyba T, Randi G, Bray F, Martos C, Giusti F, Nicholson N . The European cancer burden in 2020: Incidence and mortality estimates for 40 countries and 25 major cancers. Eur J Cancer. 2021; 157:308-347. PMC: 8568058. DOI: 10.1016/j.ejca.2021.07.039. View